U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047690) titled 'A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis' on June 24.
Brief Summary: The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
Study Start Date: Aug. 29
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis
Intervention:
DRUG: Nemolizumab
Subcutaneous Injection
DRUG: Placebo
Subcutaneous Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Galderma R&D
Published by HT Digital Content Services w...